Introduction
Allogeneic hematopoietic stem cell transplantation from unrelated donors (UR-HSCT) has been established as a mode of curative therapy for hematological malignancies and other hematological or immunological disorders when an HLA-identical sibling donor is unavailable. Identification of the HLA locus matching at the allele level responsible for immunological events related to HSCT is important in optimizing HLA matching and minimizing graft-versus-host disease (GVHD) and engraftment failure, as well as in enhancing the graft-versus-leukemia (GVL) effect. [1] [2] [3] In the late nineties, the Japan Marrow Donor Program (JMDP) demonstrated for the first time the effect of matching of HLA class I alleles on acute GVHD and the importance of HLA-A and -B allele matching for survival.
2) Analysis of a large cohort in the United States also indicated that HLA allele mismatching is a significant risk factor for severe acute GVHD and mortality.
3) Subsequent extensive analysis of the
JMDP, US-National Marrow Donor Program (NMDP), European registries and the
International Histocompatibility Workshop Group (IHWG) revealed considerable evidence that HLA allele compatibility, 4-11) HLA haplotype 12.13) and HLA epitope [14] [15] [16] [17] are significantly associated with clinical outcomes.
We hypothesized that the compatibility of the respective HLA loci between donor
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Here, to elucidate the biological effects of HLA locus matching on clinical outcomes, we selected pairs transplanted with T-cell-replete marrow for whom precise data for the complete HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1 alleles were obtained by retyping.
Methods

Study population
7898 unrelated donor transplant pairs from the JMDP database met the following criteria and were included in the analysis: 1) transplantation pairs retyped for HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1 alleles; 2) T-cell-replete marrow without in vivo use of anti-thymocyte globulin or anti-T cell monoclonal antibody for GVHD prophylaxis;
3) first transplantation; 4) Japanese ethnicity; and 5) survival for more than 7 days after transplantation. All pairs were transplanted between January 1993 and December 2010.
A total of 12502 pairs were facilitated through the JMDP during this period. The present 7898 study pairs with retyped HLA data consisted of 74.7% of the 10575 pairs who Table 1 . Standard-risk leukemia was defined as chronic myeloid leukemia (CML) in the first chronic phase or acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML) in the first complete remission (CR) at the time of transplantation, and diagnosed in 2508 patients, while high-risk leukemia was defined as transplantation at a more advanced stage than in standard-risk leukemia, and was diagnosed in 2772 patients. Sex matching between donor and patient was female (donor) to male (patient) in 1494 pairs, male to male in 3253, female to female in 1442, and male to female in 1709. For GVHD prophylaxis, no patient had in vivo use of anti-thymocyte globulin or a monoclonal antibody such as CAMPATH-1H.
Tacrolimus-based regimens were employed in 4779 patients, in combination with methotrexate in 4529; cyclosporine-based regimens were used in 3078, in combination with methotrexate in 2993; and other regimens were used in 41. The conditioning regimen was classified as myeloablative if it included total body irradiation (TBI) ≥ 8 Gy, oral busulfan (Bu) ≥ 9 mg/kg, intravenous Bu ≥ 7.2 mg/kg, or melphalan >140 mg/m 2 ; otherwise, it was classified as a reduced intensity regimen.
Transplantation conditioning was done with a myeloablative regimen in 6653 patients
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Statistical analysis
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Overall survival was calculated using the Kaplan-Meier method. Competing events were defined as death without acute GVHD for acute GVHD; death without chronic GVHD for chronic GVHD; death without neutrophil engraftment for neutrophil engraftment; and death without relapse for leukemia relapse. 1.24 p<0.001 and 1.36 p<0.001, respectively), but was not significant for HLA-DQB1 (Table 2) .
RR of HLA allele mismatch compared with HLA allele match for chronic GVHD was significant for HLA-C (RR 1.24 p<0.001), but not significant for HLA-A, -B, -DRB1, -DQB1 or -DPB1 ( Table 2) .
Effect of HLA locus matching on survival.
RR of HLA allele mismatch compared with HLA allele match for mortality was highly significant in the HLA-class I locus, namely HLA-A (1.29 p<0.001), HLA-B (1.27 p<0.001) and HLA-C (1.21 p<0.001), but was not significant in the HLA-class II locus, namely HLA-DRB1, -DQB1 and -DPB1 (Table 3) .
Positive interaction of HLA-DRB1 mismatch and HLA-DQB1 mismatch in the risk of acute GVHD and survival.
As HLA-DRB1 and HLA-DQB1 matching are closely linked in the HLA region and matching probability for HLA-DRB1 and HLA-DQB1 was 89%, stratified analysis of HLA-DRB1 matching and HLA-DQB1 matching was performed (Table 4) . Pairs with HLA-DRB1 and HLA-DQB1 double (DRB1_DQB1) mismatch showed a significant risk of acute GVHD compared with pairs with both DRB1_DQB1 match (RR of grade III-IV, 1.32 p<0.001; and RR of grade II-IV, 1.34 p<0.001)). HLA-DRB1 mismatch alone or HLA-DQB1 mismatch alone showed no significant difference in either grade III-IV or grade II-IV acute GVHD from DRB1_DQB1 match, respectively. Thus, DRB1_DQB1 mismatch induced a greater effect on acute GVHD than would be expected from the independent effect of either HLA-DRB1 or HLA-DQB1 mismatch alone.
As with acute GVHD, stratified analysis of both HLA locus matching showed that pairs with DRB1_DQB1 mismatch were at significantly higher risk of mortality than pairs with DRB1_ DQB1 match (RR 1.17 p<0.001) ( Table 4 ). In contrast, risk with HLA-DRB1 mismatch alone or HLA-DQB1 mismatch alone was not significantly different from that with DRB1_DQB1 match (RR 1.04 p=0.662 and RR 1.04 p=0.532, respectively).
The risk of double HLA locus mismatch combinations other than DRB1_DQB1 for grade III to IV acute GVHD and mortality were analyzed. As shown in Supplemental table S3, none of these double mismatch combinations revealed an epistatic effect of double HLA locus mismatch.
The same results were obtained using the same stratified analysis of HLA-DRB1 or -DQB1 (Table 3) .
Independence of GVL effect of HLA-DPB1 mismatch from chronic GVHD.
As described above, HLA-DPB1 mismatch induced the GVL effect, but did not induce chronic GVHD. Chronic GVHD also induced the GVL effect. Therefore, the GVL effect of HLA-DPB1 matching in relation to chronic GVHD was analyzed in 2129 leukemia patients with HLA-A, -B, -C, -DRB1 and -DQB1 allele complete match donors who survived 100 or more days after transplantation. Multivariate competing risk regression analysis, including HLA-DPB1 matching and chronic GVHD, were performed with chronic GVHD treated as a time-dependent covariate ( significantly lower leukemia relapse risk than no chronic GVHD. Further, one and two DPB1 allele mismatch was associated with a significantly lower leukemia relapse risk than HLA-DPB1 match. Interaction analysis between HLA-DPB1 matching and chronic GVHD was not significant (RR 1.26 95%CI 0.85-1.88 p=0.255), indicating the lack of any effect modification between HLA-DPB1 matching and chronic GVHD.
When acute GVHD was added to this analysis, RR of grade III-IV acute GVHD and grade II-IV acute GVHD was 0.77 (95%CI 0.57-1.04, p=0.091) and 0.82 (95%CI 0.68-0.99, p=0.038), respectively. Thus, the effect of acute GVHD on leukemia relapse was not significant in patients who survived more than 100 days after transplantation.
Effect of HLA locus matching on neutrophil engraftment. Engraftment risk of neutrophils at 100 days after transplantation was assessed in all patients. Although RR of engraftment by HLA locus mismatch in the HVG direction showed the relatively lower risk range of 0.91 to 0.97 compared with HLA locus match in all 6 HLA loci, there was no significant HLA locus matching for neutrophil engraftment (Table 4) .
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As the above HLA locus matching analysis indicated that multiple HLA locus mismatch was associated with a higher risk of adverse clinical outcomes of acute GVHD and survival, we next explored the appropriate HLA mismatch locus combination which revealed the effect of the number of HLA mismatch loci for acute GVHD and survival.
The number of HLA one-allele mismatches was summed after exclusion of two-allele mismatches in each HLA locus. The combination of HLA-DRB1 one-allele mismatch and HLA-DQB1 one-allele mismatch (DRB1_DQB1 mismatch) was adopted and treated as one HLA locus mismatch. Significant variables (p-value less than 0.01) other than HLA locus matching for acute GVHD, chronic GVHD, leukemia relapse, neutrophil engraftment, and mortality are listed in Table 6 . Patient age affected acute GVHD, chronic GVHD and mortality, and donor age affected chronic GVHD and mortality. Compared with ALL, CML showed a lower risk of chronic GVHD, leukemia relapse and mortality, and a higher risk of neutrophil engraftment. AML showed a lower risk of mortality, and aplastic anemia showed a lower risk of acute GVHD, chronic GVHD and mortality. A reduced conditioning regimen showed a higher risk of acute GVHD (grade III -IV) compared with a myeloablative regimen. Tacrolimus-based GVHD prophylaxis showed a higher rate of neutrophil engraftment compared with cyclosporine-based GVHD prophylaxis, but no increase for acute GVHD and chronic GVHD. Sex matching conversely affected acute GVHD and neutrophil engraftment. ABO blood type matching and transplanted cell number affected neutrophil engraftment. The passage of time, reflecting an improvement in clinical selection for variables, was associated with a lower risk of mortality as a whole. RR of all variables for each factor are shown in Supplemental Our stratified analysis showed that the concurrent presence of HLA-DRB1 mismatch and HLA-DQB1 mismatch was associated with a high risk of severe acute GVHD and mortality, whereas the presence of HLA-DRB1 mismatch or HLA-DQB1 mismatch only did not induce a significantly higher risk of severe acute GVHD or survival. This epistasis of two HLA locus mismatch needs to be interpreted with care. In particular, the relatively small number of DRB1 alone mismatch pairs (n=325) might have limited the statistical power. An additional consideration is that no other HLA 2 locus mismatch combination showed such an epistatic effect of DRB1 and DQB1 on the risk of severe acute GVHD and mortality (Supplemental table S3). Interaction of the HLA-DQB1 molecule with that of HLA-DR groups might evoke unique immune reactions related to allogeneic transplantation for severe acute GVHD. As reported by Fernandez Vina et al, 28 ) the effect of the low expression of HLA loci, not only of DP, DQ but also the DRB3/4/5 locus, needs to be explored.
As also reported by Shaw et al 8) , the present study found that HLA-DPB1 mismatch induced acute GVHD and the GVL effect, but did not affect survival.
HLA-DP antigen was originally typed using the in vitro primed lymphocyte test. From this, HLA-DPB1 and its matching are known to play a distinct biological role in Our analysis also provides further information for personalized unrelated donor selection. In cases where the transplant team is particularly concerned about the prevention of severe acute GVHD, leukemia relapse or early mortality, the specific HLA locus mismatches and number of mismatched locus should be considered with regard to the patient's disease, disease status and clinical condition. The benefit of HLA-C mismatch and HLA-DPB1 mismatch for a specific GVL effect in leukemia patients is noted.
A number of other important factors will also impact clinical outcomes and change the magnitude of the HLA barrier. In the present study, clinical risk factors other than 
41) Our findings need to be validated using unrelated donor transplantation data for other ethnic groups.
In conclusion, we clearly determined the HLA locus mismatches responsible for diverse transplant-related immunological events. Further, we provide a rationale for the development of an algorithm for unrelated donor selection.
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